Skip to content

A Clinical study to compare the Efficacy & Safety of Instavit instant energy oral spray for the fatigue condition

â??A Prospective, Interventional, Single center, Randomised, Double blind, Placebo Controlled, clinical study to evaluate the Efficacy & Safety of Instavit® instant energy oral spray in the implications on health and performance on everyday fatigue condition and improvement of alertnessâ??.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011170
Enrollment
50
Registered
2018-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: null- Fatigue condition

Interventions

Intervention1: Instavit® Instant energy 14ml/0.5 Fl OZ : Oral energy Supplement with Caffeine and Vit B12 Spray 1-4 times into your mouth or under your tongue For 28 days Control Intervention1: Place

Sponsors

Instavit Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Mentally, physically and legally eligible to give informed consent. 2. Male and female BMI between 20.0 â?? 25.9 kg/m2 3. Subject meet criteria for fatigue as per Chalder Fatigue Assessment scale. 4. Subjects willing and able to provide informed consent voluntarily 5. Patient is willing and able to comply with all trial requirements

Exclusion criteria

Exclusion criteria: 1. Significant medical or psychiatric illness 2. Subjects having history of drug or alcohol abuse 3. Previous receipt of Study Drug 4. History of HIV, HAV, HBs Ag 5. Volunteers who have participated in any drug research study within past 3 months. 6. Presence or history of hypersensitivity to any of the active or inactive ingredients 7. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
1. Improvement in fatigue level by using Fatigue assessment test 2. Changes in severity of fatigue by using Fatigue Severity scale 3. Improvement in overall condition by assessing the Changes in Piper fatigue scale from baseline to EOT Timepoint: from baseline to End Of Treatment(28 days)

Secondary

MeasureTime frame
1. Assessment of energy level by using Ergometer for instant energy. 2. Changes in Chalder Fatigue Assessment scale. 3. Incidence and Rate of adverse events. Timepoint: from baseline to End Of Treatment (28 days)

Countries

India

Contacts

Public ContactDr Harisha s

ICBio Clinical Research Pvt. Ltd.

harish@icbiocro.com9900111997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026